Natco Pharma Gains 7.33%: 5 Key Factors Driving the Week’s Momentum

6 April: Technical Momentum Shifts Signal Bullish Outlook

Natco Pharma began the week with a notable shift in technical momentum, moving from mildly bullish to bullish. The stock closed at Rs.1,028.50, supported by positive MACD signals on weekly charts and expanding Bollinger Bands, indicating increased volatility with an upward bias. The Relative Strength Index (RSI) remained neutral, suggesting room for further gains without immediate overbought risk. Despite mixed longer-term signals from the KST and Dow Theory, the short-term outlook was optimistic, setting the stage for the week’s rally.

7 April: New 52-Week High at Rs.1,075 Amid Market Caution

On 7 April, Natco Pharma surged to a new 52-week high of Rs.1,075, closing at Rs.1,081.40, a 5.14% gain on the day. This marked the second consecutive day of strong gains, with the stock outperforming the Pharmaceuticals & Biotechnology sector by 4.04%. The broader Sensex was subdued, declining 0.50%, highlighting Natco Pharma’s relative strength. The stock traded above all key moving averages, reinforcing the bullish technical setup and signalling sustained buying interest.

8 April: Continued Rally with 52-Week High of Rs.1,113.8

Natco Pharma extended its winning streak to five sessions on 8 April, hitting a fresh 52-week high of Rs.1,113.8. The stock closed at Rs.1,111.60, up 2.79% for the day, delivering an 11.56% return over the five-day span. Although it slightly underperformed its sector by 0.36% on the day, the overall momentum remained robust. Technical indicators including MACD and Bollinger Bands continued to support the bullish trend, while the stock maintained its position above all major moving averages.

9 April: New 52-Week High at Rs.1,127.5 Despite Market Weakness

On 9 April, Natco Pharma reached yet another 52-week high of Rs.1,127.5, closing at Rs.1,124.45, up 1.16% on the day. This marked six consecutive sessions of gains and a cumulative 15.59% return since the start of the rally. The stock outperformed its sector by 0.74% even as the Sensex declined by 1.2%, underscoring its resilience. Technical indicators remained bullish, with MACD positive on weekly and monthly charts and Bollinger Bands expanding. The stock’s position above all key moving averages further confirmed the sustained upward momentum.

10 April: Fresh 52-Week High at Rs.1,134.9 Closes the Week

Natco Pharma capped the week by hitting a new 52-week high of Rs.1,134.9 on 10 April, closing at Rs.1,103.90. Despite a slight intraday decline of 1.83%, the stock delivered a strong weekly gain of 7.33%, outperforming the Sensex’s 5.34% rise. The seven-day winning streak yielded a cumulative return of 15.69%. Technical indicators including MACD, Bollinger Bands, and On-Balance Volume remained bullish, while the Relative Strength Index suggested the stock was not yet overbought. The Mojo Score of 64.0 and Hold rating reflect a balanced but positive outlook amid ongoing sectoral strength.

Daily Price Performance vs Sensex

Key Takeaways

Strong Technical Momentum: Natco Pharma’s week was characterised by a clear bullish technical shift, with MACD bullish on weekly and monthly charts, expanding Bollinger Bands, and the stock consistently trading above all major moving averages. These indicators collectively signal sustained upward momentum.

Consistent New Highs: The stock hit new 52-week highs on four consecutive trading days, culminating in a peak of Rs.1,134.9 on 10 April. This reflects robust buying interest and confidence in the stock’s near-term prospects.

Outperformance vs Sensex: Natco Pharma outpaced the Sensex by nearly 2 percentage points over the week, highlighting its relative strength amid a mixed broader market environment where the benchmark index showed volatility and intermittent declines.

Mojo Score and Rating Upgrade: The MarketsMOJO score of 64.0 and Hold rating, upgraded from Sell in March, align with the technical and price momentum observed, suggesting a cautiously optimistic stance on the stock’s medium-term outlook.

Sectoral Resilience: Despite broader market caution and the Sensex trading below key moving averages, Natco Pharma’s performance within the Pharmaceuticals & Biotechnology sector underscores its differentiated strength and potential for continued gains.

Conclusion

Natco Pharma Ltd. demonstrated a compelling performance during the week of 6 to 10 April 2026, delivering a 7.33% gain and consistently setting new 52-week highs. Supported by strong technical indicators and a favourable relative performance against the Sensex, the stock’s momentum reflects renewed investor confidence within the pharmaceuticals sector. The upgrade to a Hold rating by MarketsMOJO further corroborates this positive shift. While some caution remains due to mixed longer-term signals and broader market volatility, Natco Pharma’s resilience and technical strength position it as a notable small-cap performer in the current market environment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →